BioStem Technologies (BSEM) Projected to Release Earnings on Wednesday

BioStem Technologies (OTCMKTS:BSEM) is expected to issue its Q2 2026 results after the market closes on Wednesday, August 12th. Analysts expect BioStem Technologies to announce earnings of ($0.50) per share and revenue of $6.3520 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.

BioStem Technologies (OTCMKTS:BSEM) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.24). The business had revenue of $6.14 million for the quarter, compared to analyst estimates of $5.70 million. On average, analysts expect BioStem Technologies to post $-2 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

BioStem Technologies Stock Down 7.6%

BSEM opened at $3.78 on Tuesday. The firm has a 50-day moving average price of $3.67 and a 200-day moving average price of $4.64. BioStem Technologies has a twelve month low of $3.01 and a twelve month high of $10.71. The company has a market capitalization of $67.41 million, a price-to-earnings ratio of -3.39 and a beta of 0.11.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright began coverage on shares of BioStem Technologies in a research note on Wednesday, May 6th. They issued a “buy” rating and a $9.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, BioStem Technologies currently has a consensus rating of “Buy” and a consensus price target of $9.00.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr.